UCB, INC. CORDIALLY INVITES YOU TO ATTEND

BRIVIACT® (brivaracetam) CV

AN EDUCATIONAL PROGRAM

ON BRIVIACT

PRESENTED BY:

Jennifer L. Berkeley, MD, PhD

Director of Neurocritical Care, Sinai Hospital of Baltimore

Wednesday, April 26, 2023
6:45 PM EST

Hamilton's On Main
102 E Main St, Newark, DE

RSVP BY:

Friday, April 21, 2023

Seating is limited. Please reply as soon as possible to guarantee your seat.

For more information, or to reserve your place, contact your **UCB representative:**

Specialist: Deborah Zehe **Ph: 240-532-9138** **Email: Deborah.Zehe@ucb.com**

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not appropriate, and associated expenses will not be reimbursed. Certain state and federal requirements place restrictions on and/or require disclosure of items UCB provides to healthcare professionals, including meals and refreshments. UCB is committed to complying with all legal requirements.

UCB will not provide alcohol at this program. Please do not forward the invitation.

INDICATION

BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.

IMPORTANT SAFETY INFORMATION

BRIVIACT is associated with important warnings and precautions including suicidal behavior and ideation, somnolence, fatigue, dizziness, disturbance in gait and coordination, psychiatric adverse reactions including nonpsychotic and psychotic symptoms, and hypersensitivity reactions (bronchospasm and angioedema). BRIVIACT is contraindicated in patients with a prior hypersensitivity reaction to brivaracetam or any of the inactive ingredients.

In adult adjunctive therapy placebo-controlled clinical trials, the most common adverse reactions (at least 5% for BRIVIACT and at least 2% more frequently than placebo) were somnolence and sedation, dizziness, fatigue, and nausea and vomiting symptoms. Adverse reactions reported in clinical studies of pediatric patients were generally similar to those in adult patients. Adverse reactions with BRIVIACT injection in adult and pediatric patients were generally similar to those observed with BRIVIACT tablets. Other adverse events that occurred in adult patients who received BRIVIACT injection included dysgeusia, euphoric mood, feeling drunk, and infusion site pain.

BRIVIACT is a Schedule V controlled substance.

Please refer to the full Prescribing Information provided by the UCB representative, and visit BRIVIACThcp.com.

Inspired by patients. Driven by science.